-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Downgrades Upstream Bio to In-Line, Lowers Price Target to $15

Benzinga·03/27/2026 14:47:32
Listen to the news
Evercore ISI Group analyst Cory Kasimov downgrades Upstream Bio (NASDAQ:UPB) from Outperform to In-Line and lowers the price target from $40 to $15.